Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-27

Clinical Trial Update: A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of pexidartinib in adults with Tenosynovial Giant Cell Tumor; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pexidartinib (pexidartinib)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Tenosynovial Giant Cell Tumor | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-04-27